Get the Stockscreener App
434.80
2.10%
8.95
Madrigal Pharmaceuticals Inc stock is traded at $434.80, with a volume of 265.11K.
It is up +2.10% in the last 24 hours and down -9.15% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$425.85
Open:
$429.86
24h Volume:
265.11K
Relative Volume:
0.79
Market Cap:
$9.87B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-17.31
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
-0.05%
1M Performance:
-9.15%
6M Performance:
+0.83%
1Y Performance:
+35.32%
1-Day Range:
$423.98
$443.61
1-Week Range:
$416.21
$448.13
52-Week Range:
$265.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
434.80 | 9.67B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-06-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-05-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-03-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Weakness - simplywall.st
Madrigal Pharmaceuticals: How Noninvasive Data Is Powering a Smarter Clinical Strategy! - Smartkarma
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by TD Asset Management Inc - MarketBeat
MDGL: Rezdiffra's growth accelerates with a broad pipeline and strong 2026 financial outlook - TradingView
Intech Investment Management LLC Lowers Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success - Finviz
Madrigal Pharmaceuticals EVP Dier sells $505k in shares By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals (NASDAQ:MDGL) CFO Mardi Dier Sells 1,183 Shares - MarketBeat
Madrigal Pharmaceuticals (MDGL) director sale notice: 1,183 shares after RSU vest - Stock Titan
MADRIGAL PHARMACEUTICALS EVP and CFO Sells Shares to Cover Tax Obligations - TradingView
Madrigal (MDGL) CFO has shares sold automatically for tax withholding - Stock Titan
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: Exploring a 54% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Rafferty Asset Management LLC Lowers Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
JPMorgan Chase & Co. Reduces Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
William Blair Investment Management LLC Has $188.88 Million Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Artisan Partners Limited Partnership Acquires 4,683 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Q4 earnings miss, MASH drug sales drive top line, stock down - MSN
MDGL SEC FilingsMadrigal Pharmac 10-K, 10-Q, 8-K Forms - Stock Titan
Fox Run Management L.L.C. Takes $1.06 Million Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Why Madrigal Pharmaceuticals (MDGL) Is Down 9.7% After Rezdiffra’s Near US$1 Billion Debut Year - Yahoo Finance
Exit Recap: Will Madrigal Pharmaceuticals Inc outperform during market ralliesEarnings Summary Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
Madrigal: The Easiest Money May Have Been Made (NASDAQ:MDGL) - Seeking Alpha
Director exercises 2,500 Madrigal (MDGL) options at $7.36 - Stock Titan
Madrigal Pharmaceuticals Reports 2025 Financial Results - MyChesCo
Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference - The Manila Times
Madrigal to webcast TD Cowen health conference talk Mar. 3 - Stock Titan
Madrigal Grants Inducement Awards to Five Employees - MyChesCo
Madrigal (MDGL) Q4 2025 Earnings Call Transcript - The Globe and Mail
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra’s First Full Year Near US$1b In Sales - simplywall.st
Madrigal Pharmaceuticals, Inc. (MDGL): Investor Outlook Reveals 53% Potential Upside In Biotechnology - DirectorsTalk Interviews
Vanguard Group Inc. Sells 65,227 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal’s Rezdiffra Breakthrough Spurs MASH Pipeline Growth And Valuation Debate - Yahoo Finance
MASH Drugs Market to hit US$ 929.05 Million by 2033 | North America - openPR.com
Madrigal Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down - Bitget
Is now the right time to enter Madrigal Pharmaceuticals Inc.July 2025 Opening Moves & Safe Entry Momentum Tips - mfd.ru
MDGL: B of A Securities Maintains Neutral Rating, Lowers Price T - GuruFocus
Bank of America Issues Pessimistic Forecast for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q4 2025 Earnings Call Transcript - Insider Monkey
Fiera Capital Corp Lowers Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal inks licensing deal with China’s Suzhou Ribo for MASH drugs - MSN
Decoding Madrigal Pharmaceuticals Inc (MDGL): A Strategic SWOT I - GuruFocus
Madrigal Pharma earnings missed by $1.97, revenue topped estimates - Investing.com Canada
Madrigal Eyes MASH Future As Rezdiffra Nears Blockbuster Revenue - Citeline News & Insights
Earnings call transcript: Madrigal Pharmaceuticals Q4 2025 misses EPS, stock dips - Investing.com India
Madrigal Pharmaceuticals Inc (MDGL) Q4 2025 Earnings Call Highlights: Record Sales and ... By GuruFocus - Investing.com Canada
Madrigal Pharmaceuticals Inc (MDGL) Q4 2025 Earnings Call Highli - GuruFocus
Madrigal Pharmaceuticals (NASDAQ:MDGL) Posts Quarterly Earnings Results, Misses Estimates By $2.61 EPS - MarketBeat
Madrigal Pharmaceuticals, Inc. reports strong Rezdiffra sales growth in Q4 2025; first full year of launch approaches $1 billion in net sales - AlphaStreet News
Madrigal Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Madrigal Pharmaceuticals (MDGL) Reports Strong Q4 2025 Performan - GuruFocus
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):